You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCLC A/B

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma by BCLC Stage Trial in Guangzhou (Bevacizumab Biosimilar QL 1101)

Not yet recruiting
  • Hepatocellular Carcinoma by BCLC Stage
  • Bevacizumab Biosimilar QL 1101
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 20, 2023

Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Hepatocellular Carcinoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 30, 2023

Hepatocellular Carcinoma by BCLC Stage Trial in Rennes (Tislelizumab)

Not yet recruiting
  • Hepatocellular Carcinoma by BCLC Stage
  • Rennes, France
    Centre Eugene Marquis
Jan 16, 2023

Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE) Trial in Guangzhou (Sorafenib,

Active, not recruiting
  • Radiomics
  • +4 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Jun 5, 2023

Hepatocellular Carcinoma Trial in Beijing (HAIC, TACE, FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • +4 more
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jan 10, 2022

BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma Trial in

Withdrawn
  • BCLC Stage B Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +3 more
  • (no location specified)
Dec 12, 2022

Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial (Atezolizumab Injection, Bevacizumab, Transarterial

Not yet recruiting
  • Hepatocellular Carcinoma
  • BCLC Stage B Hepatocellular Carcinoma
  • Atezolizumab Injection
  • +2 more
  • (no location specified)
Mar 16, 2023

Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial in Seattle

Terminated
  • Advanced Hepatocellular Carcinoma
  • +2 more
  • Cabozantinib S-malate
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Resin microspheres containing yttrium-90 (Y-90)
  • Mission Hills, California
  • +15 more
Sep 15, 2022

BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial in

Recruiting
  • BCLC Stage A Hepatocellular Carcinoma
  • +3 more
  • 18F-Fluoromisonidazole
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
May 25, 2022

Unresectable Hepatocellular Carcinoma Trial (Donafenib plus Sintilimab in combination with transarterial chemoembolisation)

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • Donafenib plus Sintilimab in combination with transarterial chemoembolisation
  • (no location specified)
Aug 17, 2022

BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma Trial in

Recruiting
  • BCLC Stage B Hepatocellular Carcinoma
  • +9 more
  • Durvalumab
  • Tremelimumab
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Hepatocellular Carcinoma Trial in Shanghai (PD-1 and Lenvatinib Plus TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1 and Lenvatinib Plus TACE
  • Shanghai, Shanghai, China
    Huashan hospital
Aug 16, 2022

Hepatocellular Carcinoma Trial in Wuhan (TACE+Lenvatininb+Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • TACE+Lenvatininb+Camrelizumab
  • Wuhan, Hubei, China
    Wuhan Union Hospital
May 27, 2021

BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma Trial in

Not yet recruiting
  • BCLC Stage B Hepatocellular Carcinoma
  • +10 more
  • Ipilimumab
  • Nivolumab
  • Miami, Florida
  • +4 more
Aug 23, 2022

Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial (Liquid Biopsy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Liquid Biopsy
  • (no location specified)
Apr 18, 2023

Hepatocellular Carcinoma Trial in Guangzhou (neo-TACE-HAIC+Surgery, Surgery alone)

Recruiting
  • Hepatocellular Carcinoma
  • neo-TACE-HAIC+Surgery
  • Surgery alone
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 22, 2020

HCC Trial in China (DEB-TACE and HAIC, DEB-TACE)

Recruiting
  • HCC
  • DEB-TACE and HAIC
  • DEB-TACE
  • Luohe, Henan, China
  • +15 more
Mar 28, 2023

HepatoCellular Carcinoma Trial in Foshan, Guangzhou, Kaiping (Hepatic arterial infusion chemo, Transarterial chemoembolization,

Unknown status
  • HepatoCellular Carcinoma
  • Hepatic arterial infusion chemotherapy
  • +3 more
  • Foshan, Guangdong, China
  • +3 more
May 12, 2020

Hepatocellular Carcinoma, Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Trial in Dallas (Atezolizumab and

Not yet recruiting
  • Hepatocellular Carcinoma
  • Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
  • Atezolizumab and bevacizumab
  • transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
  • Dallas, Texas
    Simmons Comprehensive Cancer Center at University of Texas South
Sep 9, 2022

C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou (Hepatic Arterial Infusion combined with Apatinib

Recruiting
  • C-staged Hepatocellular Carcinoma in BCLC Classification
  • Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 3, 2022

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

Hepatocellular Carcinoma Trial in Guangzhou (HAIC of FOLFOX, H101, Placebos)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC of FOLFOX
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 19, 2020

C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou, Guanzhou, Changsha (Hepatic Arterial Infusion

Recruiting
  • C-staged Hepatocellular Carcinoma in BCLC Classification
  • Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
  • Apatinib combined with Camrelizumab
  • Guangzhou, Guangdong, China
  • +4 more
Jun 15, 2022

Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage Trial in Guangzhou, Guanzhou, Changsha (Hepatic

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Hepatocellular Carcinoma by BCLC Stage
  • Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
  • Guangzhou, Guangdong, China
  • +4 more
May 4, 2022